{"filing":{"accession_number":"0001193125-26-249684","cik":"0001740279","ticker":"INAB","company_name":"IN8BIO, INC.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"d100941d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526249684/d100941d8k.htm"},"events":[{"id":7762,"run_id":6816,"accession_number":"0001193125-26-249684","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"IN8bio entered into a Capital on Demand Sales Agreement with JonesTrading on June 1, 2026, establishing an at-the-market offering program under which the Company may issue and sell shares of common stock at its discretion.","company_name":"IN8BIO, INC.","ticker":"INAB","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3091,"accession_number":"0001193125-26-249684","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"IN8bio entered into a Capital on Demand Sales Agreement with JonesTrading on June 1, 2026, establishing an at-the-market offering program under which the Company may issue and sell shares of common stock at its discretion. This is a classic ATM offering arrangement—a dilutive equity issuance mechanism that allows the company to raise capital by selling shares into the market over time. The agreement is material because it creates a potential source of dilution to existing shareholders and provides the company with ongoing liquidity access.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:20:18.673578+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":7763,"run_id":6816,"accession_number":"0001193125-26-249684","anchor_item_number":"1.02","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"IN8bio terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, which had been a material financing mechanism established in November 2022, eliminating the Company's ability to raise capital through that at-the-market offering program.","company_name":"IN8BIO, INC.","ticker":"INAB","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3092,"accession_number":"0001193125-26-249684","item_number":"1.02","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, which was a material financing mechanism established in November 2022. While Item 1.02 typically covers M\u0026A terminations, this disclosure involves termination of a material definitive agreement governing equity issuance capacity. The termination eliminates the Company's ability to raise capital through this at-the-market offering mechanism, which is material to investors assessing liquidity and financing flexibility, though it does not fit neatly into the M\u0026A or dilutive issuance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:20:18.673578+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3091,"accession_number":"0001193125-26-249684","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"IN8bio entered into a Capital on Demand Sales Agreement with JonesTrading on June 1, 2026, establishing an at-the-market offering program under which the Company may issue and sell shares of common stock at its discretion. This is a classic ATM offering arrangement—a dilutive equity issuance mechanism that allows the company to raise capital by selling shares into the market over time. The agreement is material because it creates a potential source of dilution to existing shareholders and provides the company with ongoing liquidity access.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:20:18.673578+00:00","company_name":"IN8BIO, INC.","ticker":"INAB","filing_date":"2026-06-01"},{"id":3092,"accession_number":"0001193125-26-249684","item_number":"1.02","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, which was a material financing mechanism established in November 2022. While Item 1.02 typically covers M\u0026A terminations, this disclosure involves termination of a material definitive agreement governing equity issuance capacity. The termination eliminates the Company's ability to raise capital through this at-the-market offering mechanism, which is material to investors assessing liquidity and financing flexibility, though it does not fit neatly into the M\u0026A or dilutive issuance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:20:18.673578+00:00","company_name":"IN8BIO, INC.","ticker":"INAB","filing_date":"2026-06-01"}]}